Investors |

Financial Information

Stock listing: The company’s common shares are listed and traded on the OTCQB Venture Market in the United States under the symbol LXXGF, and in Canada on the TSX Venture Exchange under the symbol LXG.

Share Structure and Capital

As of 06 July 2017 
Shares Outstanding50,441,503
Warrants Outstanding10,265,283

Options - To be granted2,175,000
Fully Diluted Market Capitalization
(62.881.786 @ USD $0.407)
$25,592,887 USD

Treasury
$1.6 M USD

Financials

2017 Downloads
Financial Statements for the period ending May 31, 2017
Management Discussion and Analysis for the period ending May 31, 2017
Financial Statements for the period ending February 28, 2017
Management Discussion and Analysis for the period ending February 28, 2017

2016 Downloads
Financial Statements for the period ending November 30, 2016
Management Discussion and Analysis for the period ending November 30, 2016
Financial Statements for the period ending September 30, 2016
Management Discussion and Analysis for the period ending September 30, 2016
Financial Statements for the period ending June 30, 2016
Management Discussion and Analysis for the period ending June 30, 2016
Financial Statements for the period ending March 31, 2016
Management Discussion and Analysis for the period ending March 31, 2016

Investor inquiries

Daryl Rebeck |  President, LexaGene
T: 1.800.215.1824
E: darylrebeck@lexagene.com

Auditors

Dale Matheson Carr-Hilton Labonte LLP
1500 – 1140 West Pender St.
Vancouver, BC
Canada V6E 4G1

Attorneys

McMillan LLP
Royal Centre, 1055 West Georgia Street
Suite 1500, PO Box 11117
Vancouver, BC
Canada V6E 4N7
Contact: Desmond Balakrishnan

Transfer agent

Computershare Investor Services Inc.